Pharma and healthcare funding declines by 85.83 per cent in february 2025

According to Tracxn report, funding in the healthcare and pharma sector declined by 85.83 per cent to $42.5 million in February 2025, compared to $300 million in January 2025. The sector also saw a 78.86 per cent decrease in funding compared to the $201 million raised in February 2024. This decline places February 2025 among the lowest-funded months in the past 12 months for the sector.

Early-stage rounds accounted for the majority of investments in February 2025, raising $34.6 million, which constituted 85.1 per cent of the total funding. Seed-stage funding contributed $7.87 million, making up 18.5 per cent of the overall investment.

MOC and Apex Kidney Care secured some of the largest funding rounds in February 2025, raising $18 million and $9 million, respectively. Elevation Capital, Endiya Partners, and Good Capital were among the most active investors during the period.